Buckingham Research Downgrades Teva Pharma (TEVA) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Nike out of World Cup contention as Adidas-outfitted teams head to final
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
Teva Pharma (TEVA) Guides FY13 EPS, Revs Below Expectations
November 30, 2012 7:02 AM ESTTeva Pharmaceutical Industries (NYSE: TEVA) said it expects FY13 adjusted EPS of $4.85 - $5.15, versus the consensus of $5.63.
The company is targeting revs of $19.5 - $20.5 billion, versus the consensus of $20.82 billion.... More
